Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis
COVID-19 Antibody Responses In Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has resulted in an ongoing global pandemic.
- Trial name
- CAR-CF (NCT05158829)
- Where
- 6 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Cystic Fibrosis
Early Intervention in Cystic Fibrosis Exacerbation
Individuals with cystic fibrosis (CF) develop chronic lung infections and suffer intermittent acute exacerbations of their lung disease.
- Trial name
- eICE (NCT01104402)
- Testing
- Home lung function and symptom monitoring
- Where
- 3 sites in United States
- Volunteers
- 267 people
- Sponsor
- Johns Hopkins University
Cirrhosis, Liver Fibrosis
Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis
Early diagnosis of liver fibrosis is useful for the follow-up and treatment of chronic liver disease. At present, the unique validated method to evaluate the liver fibrosis in children, is the liver biopsy which is an invasive…
- Conditions
- Cirrhosis, Liver Fibrosis, Portal Hypertension, Cystic Fibrosis
- Trial name
- PEDISCAN (NCT01072721)
- Testing
- Elastometry
- Where
- France
- Volunteers
- 264 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis Pulmonary Exacerbation
Markers of Pulmonary Dysbiosis Associated With Exacerbation in Patients Followed for Cystic Fibrosis
The aim objective is to identify markers of bacterial, viral and fungal pulmonary dysbiosis, associated with the occurrence of exacerbation in patients followed for cystic fibrosis.
- Trial name
- DYSBIOSE-CF (NCT03569904)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Cystic Fibrosis, Cystic Fibrosis in Children
Feasibility of a Mobile Medication Plan Application in CF Patient Care
This is a pilot, multicenter, prospective, randomized controlled study to evaluate the feasibility of an innovative medication adherence intervention utilizing a web-based, mobile medication management application [MedActionPlan®…
- Trial name
- MAP (NCT03637504)
- Testing
- MedActionPlan®
- Where
- 5 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Cystic Fibrosis (CF)
Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
Cystic Fibrosis (CF) is a genetic disease that affects multiple organs and systems. In recent years, the marketing of CFTR protein modulator drugs, such as the Elexacaftor-Tezacaftor-Ivacaftor (ETI) combination, has significantly…
- Trial name
- NCT07363304
- Testing
- Elexacaftor, Tezacaftor, Ivacaftor
- Where
- 6 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Meyer Children's Hospital IRCCS
Cystic Fibrosis, Prediabetes
Prevention of Cystic Fibrosis Diabetes
Acute systemic hyperglycemia causes oxidative stress and a pro-inflammatory response. The pro-inflammatory cytokines induced by hyperglycemia are toxic to islet insulin producing cells, and thus worsen glucose intolerance.
- Trial name
- Prevent (NCT00967798)
- Testing
- Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Emory University
Bronchiectasis, Cystic Fibrosis
Evaluating Bronchodilator Response in Patients With Bronchiectasis
Although patients with bronchiectasis tend to have non reversible obstructive patterns on pulmonary function tests (PFTs), reversible obstruction is not uncommon.
- Conditions
- Bronchiectasis, Cystic Fibrosis, Primary Ciliary Dyskinesia, Primary Immune Deficiency
- Trial name
- NCT05932316
- Testing
- spirometry, Salbutamol
- Where
- Israel
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Cystic Fibrosis
Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study
Real-world adherence to inhaled and oral therapies for cystic fibrosis (CF) patients remains discouragingly low, ranging between 31-53% for inhaled antibiotics and 41-72% for hypertonic saline.
- Trial name
- NCT02179710
- Testing
- Adherence dashboard motivational interviewing
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Landon Pediatric Foundation
Cystic Fibrosis
MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis
The aim of the study is to assess the diagnostic sensitivity of MRI to detect changes in Helbich-Bhalla scoring over time in patients with cystic fibrosis
- Trial name
- CFMR-lung (NCT03357562)
- Testing
- lung MRI
- Where
- 11 sites in France
- Volunteers
- 212 people
- Sponsor
- University Hospital, Bordeaux
Cystic Fibrosis
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance…
- Trial name
- NCT00457821
- Testing
- Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 39 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis (CF)
Sweat Testing in Infants: Comparing Sweat Collection on Upper Vs Lower Limbs
The goal of this study is to compare the rate of Quantity Not Sufficient (QNS) during sweat collection in infants under 6 months of age, using the Macroduct Advanced device for sweat testing.
- Trial name
- NCT06902363
- Testing
- Macroduct Advanced
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Sickle Cell Disease, Chronic Kidney Diseases
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
The purpose of this study is to test the efficacy of a peer support coaching intervention to improve activated chronic illness self-management versus an attention control group in 225 adolescents and young adults with childhood…
- Conditions
- Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer
- Trial name
- PiCASO (NCT03938324)
- Testing
- PiCASO Intervention Group
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Duke University
Cystic Fibrosis
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the…
- Trial name
- NCT02412111
- Testing
- Ivacaftor, Tezacaftor/Ivacaftor
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 156 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis, Siblings
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
The goal of the clinical trial is to test whether a mental health program that is delivered through the Internet works well for healthy children and adolescents with siblings with cystic fibrosis (CF).
- Conditions
- Cystic Fibrosis, Siblings, Mental Health, Internet-based Intervention
- Trial name
- NCT06012084
- Testing
- Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University of Regina
Cystic Fibrosis, Liver Fibrosis
Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
The aim of the study is to find CF patients at risk for cystic fibrosis related liver disease (CFLD). Comparison of ultrasound by two modalities and biochemical markers with histological evaluation of liver biopsy if present.
- Trial name
- NCT02603666
- Testing
- Fibroscan
- Volunteers
- 130 people
- Sponsor
- Karolinska University Hospital
Pulmonary Alveolar Proteinosis, Bronchiectasis
Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, single ascending (SAD), and multiple ascending dose (MAD) study conducted at a single clinical site within the UK.
- Conditions
- Pulmonary Alveolar Proteinosis, Bronchiectasis, Cystic Fibrosis, Acute Respiratory Distress Syndrome
- Trial name
- NCT02468908
- Testing
- Molgramostim
- Where
- United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Savara Inc.
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P.
- Trial name
- NCT00499720
- Testing
- Aztreonam Lysine for Inhalation
- Where
- 65 sites in United States, Puerto Rico
- Sponsor
- Gilead Sciences
Cystic Fibrosis
Long-term Study, Comparing Vest Therapy to Positive Expiratory Pressure (PEP) Therapy in the Treatment of Cystic Fibrosis
This study is a preliminary study designed to determine the safety and effectiveness of HFCWO using the InCourage vest system as an airway clearance technique for the treatment of CF.
- Trial name
- NCT00817180
- Testing
- Positive Expiratory Pressure (PEP), High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System
- Where
- 13 sites in Canada
- Volunteers
- 107 people
- Sponsor
- University of British Columbia
Cystic Fibrosis, Bronchiectasis
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis. The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis.
- Trial name
- NCT05865886
- Testing
- BI 1291583
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.